MarginsXMarginsX
Home › Markets › TKPHF

Takeda Pharmaceutical Co LTD (TKPHF)

TKPHF is quoted over the counter, not listed on an exchange. Takeda Pharmaceutical Co LTD files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · November 12, 2026
$43.15
No trades since Nov 12, 2026; later closes repeat the last quote
1-year return
+53.6%
Market cap
The company also trades on NYSE as TAK; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On fiscal year to March 31, 2026 (20-F)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerTKPHF, quoted over the counter
SEC CIK0001395064
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressTokyo, Japan

Warning signs

Cash runway
Cash-flow positive
595.1B JPY cash at March 31, 2026
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed June 17, 2026
Insider net buying, 12 months
-$13.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-06-17
Cash and burn595.1B JPY cash; operating cash flow 260.4B JPY a quarter.Report 2026-03-31
Shares outstanding3,159,673,660 (2026-03-31). the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures.Cover page 2026-03-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG AZSA LLC, Tokyo, JapanPCAOB Form AP 2026-07-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $13.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
4.51T JPY-152.4B JPY1.04T JPY595.1B JPY4.88T JPY4.51T JPY20-F 2026-06-17
FY 2025
2025-03-31
4.58T JPY107.9B JPY1.06T JPY385.1B JPY4.52T JPY4.58T JPY20-F 2025-06-25
FY 2024
2024-03-31
4.26T JPY144.1B JPY716.3B JPY457.8B JPY4.84T JPY4.26T JPY20-F 2025-06-25
FY 2023
2023-03-31
4.03T JPY317.0B JPY977.2B JPY533.5B JPY4.38T JPY4.03T JPY20-F 2025-06-25
FY 2022
2022-03-31
3.57T JPY230.1B JPY1.12T JPY849.7B JPY4.35T JPY3.57T JPY20-F 2024-06-26
FY 2021
2021-03-31
3.20T JPY376.0B JPY1.01T JPY966.2B JPY4.64T JPY3.20T JPY20-F 2023-06-28
FY 2020
2020-03-31
3.29T JPY44.2B JPY669.8B JPY637.6B JPY5.09T JPY3.29T JPY20-F 2022-06-29
FY 2019
2019-03-31
2.10T JPY135.2B JPY328.5B JPY702.1B JPY5.75T JPY2.10T JPY20-F 2021-06-29

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in JPY.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22025-06-27
Latest annual report20-F2026-06-17
Latest quarterly / interim6-K2026-10-29

Source: SEC EDGAR submissions feed, 710 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier